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Introduction
Anaphylaxis  is  a severe  systemic  allergic  reaction  that is
rapid  in  onset  and is  potentially  fatal.  Its  severity  varies  in
relation  to  the  affected  organs  and the  intensity  of  the  dam-
age  to these.  The  more  severe  forms  are  associated  with
airway  obstruction  (laryngeal  edema,  severe  bronchocon-
striction)  and/or  vascular  collapse  (anaphylactic  shock).1,2
The  frequency  of  anaphylaxis  ranges  from  0.03%  to  0.95%.
Its  lifetime  can  be  of  up  to  2.6%.  Although  anaphylaxis  occurs
more  frequently  in children  and  adolescents,  fatal cases
are  more  common  in adults.  Even  though  mortality  rates
are  sub-reported,  it  is  estimated  to  occur  in 0.65--2%  of
severe  anaphylaxis  cases.  Laryngeal  edema  and  cardiovas-
cular  complications  are  the main  cause  of  death.2--6
Anaphylaxis  can  occur  as  a consequence  of immunolog-
ical  and  non-immunological  mechanisms.  In  general,  the
most  frequent  form  of  anaphylaxis  is  associated  with  IgE-
mediated  hypersensitivity  reactions.  Nevertheless,  aside
from  the  mechanism  involved  in the  onset  of  response,
a  common  pathophysiological  characteristic  of  anaphylaxis
is  the  degranulation  of  basophils  and  mast  cells,  with  the
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consequent  liberation  of  mediators  of  inflammation,  includ-
ing  histamine,  leukotrienes  and prostaglandins.  The  action
of  these  mediators  in the skin,  mucous  membranes,  air-
ways,  gastrointestinal  tract,  cardiovascular  system,  and
other  target  organs,  originates  the signs and  symptoms  of
anaphylaxis.2,4 The  most  common  causes  of anaphylaxis
are  medications,  drugs  and  hymenoptera  venoms.  Other
causes  of  anaphylaxis  mediated  by  immunological  mecha-
nisms  include  allergen  immunotherapy,  latex,  occupational
allergens,  seminal  fluid,  aeroallergens  and  monoclonal  anti-
bodies.  Exercise,  some  physical  factors  (cold,  heat  and
radiation),  ethanol,  opioid  medications  and  contrast  media,
may  cause  non-immunological  anaphylaxis.  Idiopathic  ana-
phylaxis,  where  it is  not  possible  to identify  the cause,
represents  over 20%  of  all  anaphylaxis  cases.2--7
Anaphylaxis  is  characterized  by  a  varied  clinical  pre-
sentation  and  its  manifestations  include  skin,  respiratory,
ocular,  cardiovascular  and  gastrointestinal  symptoms.  Vital
functions  are compromised  in the most  severe  forms,  and
if this occurs  during  the first  minutes  after  the onset  of  the
reaction,  the risk  of  death  is  greater.1,2,8,9
Over  90%  of  the  patients  display  skin  symptoms.  Most
episodes  begin with  pruritus  and  flushing  and continue  with
the progressive  development  of  hives  and/or  angioedema.
Eyes  and  mucous membranes  can  acquire  a  congestive-like
aspect,  changes  generally  associated  with  intense  itch-
ing,  epiphora  and rhinorrhea.  Gastrointestinal  symptoms
include  abdominal  pain,  nausea,  vomiting,  and  diarrhea.
At  a  respiratory  level,  the  symptoms  can  include  tight-
ness  in  the  throat,  dysphagia,  dysphonia,  inspiratory  stridor
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and  even  signs  of  asphyxia,  which  is  caused  by  the  gen-
eration  of laryngeal  edema.  On  the other  hand,  cough,
dyspnea,  wheezing,  a  feeling  of  tightness  in the chest  may
onset  as  a  consequence  of  bronchoconstriction,  which can
also  cause  hypoxemia  and  cyanosis.  Cardiovascular  man-
ifestations  may  onset  with  tachycardia  and  a  feeling  of
dizziness  or  instability,  and  progress  until  the loss  of  con-
sciousness.  Peripheral  vasodilatation  and  the increase  in
vascular  permeability,  characteristics  of  anaphylaxis,  lead
to  hypotension  and  shock,  which  increase  heart  rate  and
reduce  coronary  perfusion.  These  cardiovascular  changes,
in  addition  to  hypoxemia  related  to  the  obstruction  of
the  airways,  reduce  cardiac  oxygenation  and  may  lead  to
arrhythmias  and  myocardium  necrosis,  which  are  causes  of
cardiac  arrest.  In  some  cases,  anaphylaxis  onset  can  be
abrupt,  like  syncope,  or  even  cause  sudden  death.  Other
manifestations  that  may  occur during anaphylaxis  are;  dis-
orientation,  anxiety,  seizures  and profuse  sweating.1,2,8--11
Approximately  20%  of patients  presenting  anaphylaxis
may  suffer  biphasic  reactions.  In these cases,  the  late  phase
begins  between  1  and  72  h after  the initial  phase,  usually
with  similar  clinical  manifestations.  No  clinical  data  has
been  identified  which  allows  the prediction  of  risk  of  late
reactions  in  a trustworthy  manner.  However,  the  patients
who  present  severe  initial  reactions  may  have a greater  risk
of  suffering  biphasic  reactions.1,8,9
Diagnosis
The  diagnosis  of anaphylaxis  is  fundamentally  clinical.  Clin-
ical  history  constitutes  the  most  important  tool  in  the
identification  of  a  patient  who  is  suffering  from  anaphylaxis
and  it  is  also  of  great  help  to  identify  its  cause.  In  addition
to the  detailed  description  of  signs and  symptoms  present  in
the  patient,  it is  important  to obtain  information  about  the
moment  of  onset  of  the  reaction,  medication  used to  treat
it,  the duration  of  the  episode  and  exposure  to  allergens  or
potential  triggers. Whenever  possible,  we  ought  to  question
the  people  who  witnessed  the event.9--13
Useful  clinical  criteria  have  been  established  for  the  diag-
nosis  of anaphylaxis,  which are  listed  in Table  1.  With  the
proper  use  of these  criteria,  it  is  possible  to  identify  over
95%  of anaphylaxis  cases.1
During the clinical  evaluation  of  the patient,  we  should
always  consider  other  conditions  which  may  occur  with  sim-
ilar  signs  and symptoms  to  those  of  anaphylaxis.  Differential
diagnoses  include:  vasovagal  reactions,  anxiety,  myocardial
dysfunction,  pulmonary  embolism,  foreign  body  aspiration,
poisoning,  hypoglycemia,  convulsive  disorders,  urticaria  and
angioedema,  hereditary  angioedema  and  asthma.  Although
urticaria  and  angioedema  may  occur  up  to  90%  of  anaphy-
laxis  episodes,  when  it occurs  without  affecting  other  organs
or  systems,  it  does  not  correspond  to  anaphylaxis  cases.9--13
Serum tryptase,  plasmatic  histamine  and  histamine
metabolites  in urine (methyl-histamine)  may  be  useful  to
confirm  an anaphylaxis  diagnosis.  The  best  time  for  its
measurement  after  the  onset  of  the  anaphylaxis  episode  is
between  1 and  6  h  for  serum  tryptase,  from  10  min to  1  h
for  histamine  and during  the first  24  h for  methyl-histamine.
Nevertheless,  these  studies  are not  always  available  and  the
administration  of the treatment  should  not  be delayed.1,10--14
On the other  hand,  as  a  part  of  the  attention  in the
emergency  service,  in  moderate  to  severe  anaphylaxis,  it is
convenient  to  perform  a  complete  blood  count,  metabolic
panel,  arterial  blood  gas,  and  chest  x-rays  in  order  to  assess
the  patient’s  general  condition  as  well  as  rule  out  other
diagnoses.9,11--13,15
Treatment
Timely  treatment  considerably  reduces  the risk  of  mortality
in  patients  with  anaphylaxis.  Management  ought  to  begin
Table  1  Clinical  criteria  for  anaphylaxis  diagnosis.
The  probability  of anaphylaxis  in a  patient  is high  when  at  least  one  of  the following  three  criteria  are  met:
1.  Acute  onset  (from  a  few  minutes  to  a  few  hours)  of  a  condition  characterized  by  affectation  of  the  skin  and/or  mucous  (ex.
hives, itching  or  generalized  flushing/edema  of  the  lips,  tongue  and/or  uvula)
AND AT  LEAST  ONE  OF  THE  FOLLOWING
a.  Compromised  breathing  (ex.  dyspnea,  wheezing  [bronchospasm],  stridor,  reduced  PEF,  hypoxemia)
b. Arterial  hypotension  or  symptoms  associated  with  circulatory  compromise  (e.g.  hypotonia  [collapse],  syncope,  incontinence)
2. Two  or  more  of  the  following  situations  which  occur  rapidly  after  exposure  to  a  probable  allergen  (a  few  minutes  to  a  few
hours):
a. Affectation  of  the skin  and/or  mucous  (ex.  hives,  itching  or  generalized  flushing/edema  of  the  lips,  tongue  and/or  uvula)
b. Compromised  breathing  (ex.  dyspnea,  wheezing  [bronchospasm],  stridor,  reduced  PEF,  hypoxemia)
c. Arterial  hypotension  or  symptoms  associated  with  circulatory  compromise  (e.g.  hypotonia  [collapse],  syncope,  incontinence)
d. Persistent  gastrointestinal  symptoms  (ex.  crampy  abdominal  pain,  vomiting)
3. Hypotension  after  exposure  to  a  known  allergen  for  this  patient  (a  few  minutes  to  a  few  hours)
a. Children:  low  systolic  BP  (according  to  age)  or  a  reduction  greater  than  30%  in the  systolic  BP
b. Adults:  systolic  BP  less  than  90  mm  Hg  or  a  decrease  greater  than  30%  in  the  systolic  BP
Source:  Adapted from Sampson H.A., et al. J  Allergy Clin Immunol 2006;117: 391-7.
PEF, peak expiratory flow; BP, blood pressure.
*Low systolic blood pressure in children is defined as less than 70  mm Hg in children from 1 month to 1 year old; less than 70 mm.
Hg + 2× years of age, in children from 1 to 10  years old, and less than 90  mm Hg in patients from 11 to 17 years old.
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Table  2  Drugs  indicated  in the  treatment  of  anaphylaxis.
Drug  Dose  and  administration
Epinephrine  • Adults:  0.3--0.5  mg  (0.3--0.5  mL  of  a  1:1000  solution)  intramuscular.
• Children:  0.01  mg/kg  (0.01  mL/kg  of  a 1:1000  solution)  intramuscular  (maximum  dosage  0.3  mg).
• The  dose can  be  repeated  every  5--15  min  if  necessary  (depending  on response).
• Intravenous  administration:  only  if  there  is  no response  to  epinephrine  administered
intramuscular.  It should  be administered  slowly  and  diluted  1:10,000,  through  an  infusion  pump
and only  by  trained  medical  personnel.
Antihistamines  • H1  Antagonists.  Diphenhydramine:  25--50  mg  in  adults;  1 mg/kg  (up  to  50  mg)  in children.
Intravenous  administration  should  be  slow.  Intramuscular  administration  is an  alternative.  Oral
intake can  be  considered  in  less  serious  cases.
• H2  antagonists.  Ranitidine:  50  mg  in adults  and  1  mg/kg  (up  to  50  mg)  in children.  IV
administered over  5  min,  diluted  in a  glucose  solution  at  5%.
Corticosteroids  • Methylprednisolone:  1--2 mg/kg/day  or  an equivalent  dose  of  hydrocortisone  (4--8  mg/kg).
Intravenous  administration  every  6 h.  Oral  prednisone  0.5  mg/kg;  useful  in less  serious  cases.
Bronchodilators  • Beta-2  agonist.  Nebulized  salbutamol,  2.5--5  mg  in 3 mL  of  saline  solution  or 2--6  puffs  of  MDI.
Repeat  as  necessary  (every  20  min).
Crystalloid  solutions  • 0.9%  saline  solution.  Adults:  0.5--1  L  in the first  5--10  min.  Some  cases  may  require
administration  of  up  to  7 L  in total.  Children  may  receive  up  to  30  mL/kg  in the  first  hour.
Vasopressors  • Dopamine:  400 mg  in 500  mL  of  glucose  solution  at  5%;  infuse  at a  dosage  of  20  g/kg/min.  Use
only when  there  is no adequate  response  to  treatment  with  epinephrine  intramuscular  and
infusion with  intravenous  fluids,  or  if  the  hypotension  is severe.
Glucagon  • Initial  dosage:  1--5 mg  in  adults  and  20--30  g/kg  (maximum  dosage  of  1  mg)  in  children.
Intravenous administration  over  5  min.  Maintenance  dosage:  intravenous  infusion  (5--15  g/min).
with  an  evaluation  and  the maintenance  of  airways,  venti-
lation  and  circulation.1,9--15
If the  patient  meets  clinical  criteria  for  an anaphylaxis
diagnosis,  epinephrine  should  be  administered  immediately.
The  recommended  dose  is  0.01  mg/kg  (maximum  dose  of
0.3  mg  in  children  and  0.5  mg in adults)  administered  intra-
muscular  in the antero-lateral  area  of  the thigh,  repeating
every  5--15  min  if necessary  (Table  2). Intravenous  adminis-
tration  is  an option  in  patients  with  severe  hypotension  or
cardiovascular  collapse  who  do  not  respond  to treatment
with  intramuscular  epinephrine  and intravenous  fluids.  Nev-
ertheless,  due  to  the  risks  of  lethal  arrhythmia,  the  latter
form  of  administration  should  be  considered  only when  con-
tinuous  cardiac  monitoring  is  possible.1,2,4,8--16
The  need  for therapeutic  procedures  in addition to  the
administration  of  epinephrine  in the patient  with  anaphy-
laxis  should  be  individualized  according  to  the present
situation  in  each particular  case  and  the  response  to  treat-
ment. 9--16 These  measures  include:
•  Monitoring  of  vital  signs and  surveillance  of the level of
consciousness.
•  Supine  position  with  elevation  of  lower  extremities  in case
of  hypotension.
•  Canalization  of  the peripheral  venous  way.
•  Ventilatory  assistance  with  a  bag-valve-mask  device.  Con-
sider  endotracheal  intubation  or  cricothyroidotomy  if the
severity  of  the  episode  requires  it.
•  Administration  of  oxygen  (6--8  L/min).  Pulse  oximetry  is  a
guide  to  determine  the  oxygen  requirements.
•  Fluid  resuscitation.  The  use  of crystalloid  solutions
(normal  saline) is  preferred  (Table  2).  Colloid  volume
expanders  are  an  option,  but  they  have  not shown  be
better  than  crystalloid  solutions  for  the treatment  of
hypotension  in anaphylaxis.
•  Antihistamines.  They  are  second  line  drugs  in anaphylaxis.
Antihistamines  may  be  useful  for  the treatment  of  cuta-
neous  and  mucous  membranes  symptoms.  In anaphylaxis,
it  is  recommended  the  use  of  a  combination  of H1  and  H2
antagonists  (Table 2).
•  Inhaled  beta-2  adrenergic  agonists,  if there  is  bron-
chospasm  resistant  to  epinephrine  (Table 2).
•  Corticosteroids.  Although  they  are  not useful  in the  early
phase  of  anaphylaxis,  they  can  potentially  reduce  the  risk
of  late  phase  reactions  (Table  2).
• In cases  of  hypotension  refractory  to treatment  with
intravenous  fluids  and  epinephrine,  The  administration
of  vasopressors  should be considered,  with  the  aim  of
maintaining  arterial  pressure  above  90  mm Hg.  Continuous
hemodynamic  monitoring  is  necessary  (Table  2).
•  Glucagon  is  an alternative  in  patients  who are undergo-
ing  treatment  with  beta-adrenergic  blockers  and  do not
respond  to  treatment  with  epinephrine  (Table  2).
• Vasopressors.  If epinephrine  injections  and  fluid  resusci-
tation  fail  to alleviate  hypotension,  vasopressors  (such  as
dopamine)  should  be administered  (Table  2).
• If the patient  presents  cardiopulmonary  arrest,  life  sup-
port  maneuvers  should  be applied  and  the patient  should
be  transferred  to  an intensive  care  unit,  if necessary.
Considering  the possibility  of  late  reactions,  an  obser-
vation  period  is  recommended  after  the  early  phase,  even
though  the  symptoms  may  have  disappeared  with  the initial
attention.  The  observation  periods  should  be personalized.
In most  cases,  a 4--6  h  observation  period  in  emergency
services  is  reasonable.  However,  in patients  with  severe
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symptoms  or  refractions  to the treatment,  the  observation
period  should  be  longer.  The  need  of  hospitalization  should
be  considered  in cases  of  respiratory  or  cardiovascular
compromise  which  puts the patient’s  life  at risk,  anaphy-
laxis  refractory  to  the  initial  treatment,  late  reactions,  and
patients  with  a  significant  risk  of  severe  complications  due
to  pre-existing  cardiac  or  pulmonary  diseases.1,8--16
Discharge  recommendations
Discharge  recommendations  for  a  patient  who  has  suffered
an  anaphylaxis  episode  should  include:
1.  A  prescription  of self-administered  epinephrine  in case  of
a  new  episode  of  anaphylaxis.  The  use  of auto-injector
devices  is  recommended  whenever  possible.
2.  Provide  a  written  emergency  plan  guiding  the patient  on
the  steps  to  take  in  case  of  onset  of  anaphylaxis  symp-
toms.
3.  Instructions  and  enough  information  on  the  nature  of
their  problem  should  be  provided,  as  well  as  how  to  avoid
exposure  to allergens  or  potential  triggers.
4.  Refer  the  patient  to  an allergist  for  his/her  study and pos-
sible  identification  of  the specific  cause  of  anaphylaxis,
as  well  as to  evaluate  the possibility  of  a  desensitization
treatment  or  specific  allergen  immunotherapy.9--16
Conclusions
Anaphylaxis  is  a systemic  reaction,  it is  life-threatening  and
it  has  a  rapid  onset.  The  most  frequent  triggers  are medi-
cations,  foods  and  hymenoptera  venom.  Diagnosis  is  based
on clinical  criteria.  Clinical  manifestations  include  skin,
respiratory,  cardiovascular  and  gastrointestinal  signs and
symptoms.  Epinephrine  (intramuscular)  is  the  first  choice
of  treatment  and  should  be  administered  as  soon  as  the
anaphylaxis  diagnosis  is made.  Treatment  additional  to  the
epinephrine  will  depend  on  the clinical  manifestations  of
each  case.  The  patient’s  observation  period  after  the  atten-
tion  of  the  early  phase  should  be  individualized  according  to
the  severity  of  the anaphylaxis.  At  the  moment  of  hospital
discharge,  self-administration  of  epinephrine  should  always
be  prescribed  for all  patients  who  suffered  anaphylaxis.  It is
essential  to  provide  a  written  action  plan  in case  of  future
events  of  anaphylaxis  and to  refer  the  patient  to  an allergist
for  long-term  attention.
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